Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [1] Comparison of the Efficacy of Repaglinide versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes
    Okada, Hiroshi
    Tanaka, Muhei
    Hasegawa, Goji
    Nakajima, Hanako
    Kadono, Mayuko
    Okada, Yuki
    Hirata, Atsuhiro
    Oyamada, Hirokazu
    Yamane, Tetsuro
    Fukui, Michiaki
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (43) : 4600 - 4605
  • [2] Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus
    Ono, Yuri
    Kameda, Hiraku
    Cho, Kyu Yong
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (04) : 361 - 370
  • [3] Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus
    Inoue, Masahiro
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2257 - 2268
  • [4] Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
    Konya, Hiroyuki
    Katsuno, Tomoyuki
    Tsunoda, Taku
    Yano, Yuzo
    Kamitani, Mai
    Miuchi, Masayuki
    Hamaguchi, Tomoya
    Miyagawa, Jun-Ichiro
    Namba, Mitsuyoshi
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 317 - 325
  • [5] Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naive Japanese patients with type 2 diabetes mellitus
    Suzuki, Ryo
    Eiki, Jun-ichi
    Moritoyo, Takashi
    Furihata, Kenichi
    Wakana, Akira
    Ohta, Yukari
    Tokita, Shigeru
    Kadowaki, Takashi
    DIABETES OBESITY & METABOLISM, 2018, 20 (09) : 2274 - 2281
  • [6] Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus
    Katsuno, Tomoyuki
    Watanabe, Nobuaki
    Nagai, Etsuko
    Okazaki, Kazumi
    Yokoyama, Ariko
    Hamaguchi, Tomoya
    Miyagawa, Jun-ichiro
    Namba, Mitsuyoshi
    JOURNAL OF DIABETES INVESTIGATION, 2011, 2 (03) : 204 - 209
  • [7] Effect of pantoprazole on insulin secretion in drug-naive patients with type 2 diabetes
    Gonzalez-Ortiz, Manuel
    Martinez-Abundis, Esperanza
    Mercado-Sesma, Arieh R.
    Alvarez-Carrillo, Rebeca
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (01) : E11 - E13
  • [8] Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial
    Fujimoto, Kanta
    Shibayama, Yui
    Yamaguchi, Eriko
    Honjo, Sachiko
    Hamasaki, Akihiro
    Hamamoto, Yoshiyuki
    JOURNAL OF DIABETES, 2018, 10 (08) : 675 - 682
  • [9] Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
    Iwamoto, Y.
    Tajima, N.
    Kadowaki, T.
    Nonaka, K.
    Taniguchi, T.
    Nishii, M.
    Ferreira, J. C. Arjona
    Amatruda, J. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (07) : 613 - 622
  • [10] REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAIVE SUBJECTS WITH TYPE 2 DIABETES
    Kutoh, Eiji
    Wada, Asuka
    Hayashi, Jyunka
    ENDOCRINE PRACTICE, 2018, 24 (12) : 1063 - 1072